Last week was not a standout for initial public offerings (IPOs). There were three on the calendar, and only a blank-check company was able successfully to launch in the public markets.

Two holdovers from last week, Oasmia Pharmaceutical and Boxlight, are scheduled to have another go, and so are seven health care companies, a food service distributor and a China-based shoe-sole maker.

Through the week ending September 25, IPO ETF manager Renaissance Capital reported that 134 IPOs have priced in the United States so far this year, down about 35% from a year ago. Total proceeds raised through last week equaled $22.6 billion, down about 67% compared with the same period in 2014. Of the 134 IPOs that have gone off this year, 61 have come from the health care sector. Last year’s IPO total came in at $85.2 billion, the highest total in the past 10 years. Renaissance Capital does not include “best efforts” or blank-check companies in its totals.

One offering postponed from last week is Sweden-based Oasmia Pharmaceutical. The pharmaceutical company plans to list American depositary shares (ADSs) on the Nasdaq under the ticker symbol OASM. The company’s shares already trade on the Nasdaq Stockholm exchange and on the Frankfurt exchange. The sole bookrunner is Ladenburg Thalmann, and the co-manager is Aegis Capital. The company plans to price an unspecfied number of ADSs in a range of $5.25 and $7.75 per ADS and raise $23 million. One ADS is equal to three ordinary shares. The offering is indicated only for the week of September 28. Renaissance Capital does not count this as an IPO in its statistical summaries.

The other holdover from last week, Boxlight, is a technology company primarily focused on the education and learning industry. The company plans to offer 1.1 million shares in an expected price range of $8 to $10 to raise $10 million at an implied market cap of $58 million. Sole bookrunner for the offering is Aegis Capital. Shares are indicated only to begin trading during the week of September 28 on the Nasdaq under the ticker symbol BOXL. This is Boxlight’s third try after postponing a planned offering in late August.

Mirna Therapeutics is a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics. The company plans to offer 4.65 million shares in an expected price range of $13 to $15 to raise about $65 million at an implied market cap of $233.5 million. Joint bookrunners for the offering are Citigroup and Leerink Partners. Co-managers are Oppenheimer and Cantor Fitzgerald. The offering is expected to price Tuesday and begin trading Wednesday on the Nasdaq under the ticker symbol MIRN.

Edge Therapeutics isa clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions. The company plans to offer 5.67 million shares in an expected price range of $14 to $16, raising $85 million at an implied market cap of $387.8 million. Joint bookrunners for the offering are Leerink Partners and Credit Suisse. Co-managers are Guggenheim Securities and JMP Securities. Shares are scheduled to price on Wednesday and begin trading Thursday on the Nasdaq under the ticker symbol EDGE.

Fuling Global is a Cayman Islands-based specialized production and distribution company for environmentally friendly plastic serviceware with manufacturing plants in China and the United States. The company plans to offer 5 million shares in an IPO price range of $5 to $7 to raise $30 million at an implied market cap of $100 million. Sole bookrunner for the offering is Burnham Securities. Shares are set to price Wednesday and begin trading Thursday on the Nasdaq under the ticker symbol FORK.

Performance Food Group is the third largest company in the growing $231 billion U.S. foodservice distribution industry, which supplies the diverse $611 billion U.S. “food-away-from-home” industry. The company plans to offer 14.5 million shares in an expected price range of $22 to $25, raising approximately $341 million at an implied market cap of about $2.35 billion. Joint bookrunners for the offering are Credit Suisse, Barclays, Wells Fargo Securities and Morgan Stanley. Co-managers include Blackstone Capital Markets, BB&T Capital Markets, Guggenheim Securities and Macquarie Capital. Shares are set to price Wednesday and begin trading Thursday on the New York Stock Exchange under the ticker symbol PFGC.

Surgery Partners is a health care services company with a differentiated outpatient delivery model focused on providing high-quality, cost effective solutions for surgical and related ancillary care in support of patients and physicians. The company is offering 14.3 million shares in an expected price range of $23 to $26 to raise $350 million at an implied market cap of about $1.18 billion. Joint bookrunners for the offering are Merrill Lynch, Goldman Sachs, Jefferies, Citigroup, Morgan Stanley, Credit Suisse, Raymond James and RBC Capital Markets. The sole co-manager is Stifel. Shares are set to price Wednesday and begin trading Thursday on the Nasdaq under the ticker symbol SGRY.

NovoCure is a commercial-stage oncology company developing a novel, proprietary therapy called TTFields for the treatment of solid tumor cancers. The company plans to offer 12.5 million shares in an expected price range of $26 to $29, raising about $344 million at an implied market cap of $2.36 billion. Joint bookrunners for the offering are JPMorgan, Deutsche Bank and Evercore Partners. Co-managers are Wells Fargo Securities, JMP Securities and Wedbush PacGrow. Shares are scheduled to price Thursday and begin trading Friday on the Nasdaq under the ticker symbol NVCR.

Strongbridge Biopharma is a biopharmaceutical company focused on the development, in-licensing, acquisition and eventual commercialization of multiple complementary products and product candidates within franchises that target rare diseases. The offering is a “transplant” from the Norwegian over-the-counter system. The company plans to offer 4.3 million shares at a price of $17.93, raising about $76.2 million at an implied market cap of $411.6 million. Joint bookrunners for the offering are Merrill Lynch and Stifel. Co-managers are JMP Securities, Roth Capital and Arctic Securities. Shares are expected to begin trading Friday on the Nasdaq under the ticker symbol SBBP.

Sole Elite Group, a China-based maker of shoe soles used in the manufacture of sports shoes, did not complete its IPO as planned two weeks ago. The company plans to offer 3 million shares in an expected price range of $10 to $12 to raise $33 million at a fully diluted market cap of $198 million. Joint bookrunners for the offering is Dawson James and ViewTrade. Shares are set to begin trading the week of September 28 on the Nasdaq under the ticker symbol SOLE.

ALSO READ: 10 Cities Where You Don’t Want to Get Sick

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.